PayerBiosimilar Drugs Are Cheaper Than Biologics. Are They Similar Enough to Switch?
The U.S. has been slower to adopt biosimilar drugs since the first such medicine was approved in 2015.
StrategyPublic Health Experts 'Flabbergasted' That Biden Still Hasn't Picked an FDA Chief
Many stakeholders agree that Biden's foot-dragging on finding a new director has sent the wrong message about the agency's importance.
StrategyCongress Cites KHN Investigation in Probe of National Academies
The House probe focuses on conflicts of interest held by members of a committee currently reviewing U.S. organ donation and...
Clinical CareTJC Seeking Comment on Proposed Changes to Antimicrobial Stewardship Standard
TJC is asking for your input on the changes as part of a standard field review.
PayerNovel Treatments Challenge Traditional Reimbursement
Paying for high-cost, breakthrough drugs is one of healthcare's abiding challenges?and tied to so many of the "pre-existing" conditions that...
Payer2+2=? Senate Uses Murky Math as It Shelves Drug Pricing Rule to Fund Infrastructure
The massive spending bill is the first of two likely to at least delay the so-called Medicare rebate rule released...
Covid-19Analysis: Necessary or Not, Covid Booster Shots Are Probably on the Horizon
Ultimately, the question of whether a booster is needed is unlikely to determine the FDA?s decision.
InnovationAnalytics and Hospital Pharmacies: Building a Successful Program
The requests received for data became more complex, requiring some to move away from just patient use data and incorporate...
StrategyOpinion: Why We May Never Know Whether the $56K-a-Year Alzheimer's Drug Actually Works
Though patients will start taking it, the world may have to wait many years to find out whether Aduhelm is...
MarketingDoctors Weigh Pros and Cons of Prescribing Hot-Button Alzheimer's Drug
Faced with criticism over insufficient guidance, the FDA has revised the drug's label to narrow its potential use.
StrategyWalmart Launches Private Brand Analog Insulin
The diabetes care announcement marks the latest healthcare foray by the retail giant.
PayerColorado Lawmakers Wage Multifront Assault on High Drug Costs
State officials estimate the combined impact of the various measures could save Coloradans between 20% and 40% in out-of-pocket costs.